RUO

Peptisynlab · Research Compound

BPC-157 10mg + TB-500 10mg

Co-lyophilized blend of two complementary regenerative peptides. BPC-157 (Body Protective Compound) drives angiogenesis and tissue repair; TB-500 (Thymosin β-4 fragment) mobilizes G-actin for cell migration. Together they form the most referenced research blend for tissue-repair studies.

Regeneration Angiogenesis Tissue Repair RUO

Vial Content: 20 mg total · 10 mg + 10 mg
BPC-157: Pentadecapeptide · 1419.55 g/mol
TB-500: Tβ4-fragment · ~4963 g/mol
Purity: ≥ 99% HPLC
Form: White lyophilized powder
Class: Regenerative blend

Half-life Short · variable BPC-157 short plasma t½ · TB-500 hours

Reconstitution 2 mL bac water Yields 10 mg/mL combined (5 + 5)

Storage −20 °C / 2–8 °C Lyophilized: −20 °C · Reconstituted: 2–8 °C

Route (Research) Subcutaneous Local or systemic in research models

Overview

This dual-compound research vial pairs BPC-157, a 15-amino-acid sequence derived from a gastric protective protein, with TB-500, the active fragment of Thymosin β-4. The two peptides are widely characterized in regenerative-research literature for their additive effects on healing, angiogenesis and cell migration.

BPC-157 is a partial sequence of the human gastric juice "body protective compound." It is stable in gastric environments and used in research on connective tissue, vascular and gastrointestinal repair.

TB-500 corresponds to the LKKTETQ-containing fragment of Thymosin β-4 — the principal G-actin-sequestering protein in mammalian cells. It modulates cytoskeletal dynamics, supporting cell migration to injury sites.

Mechanism of Action — How It Works

The two peptides target complementary pathways. BPC-157 acts on growth-factor cascades and nitric-oxide signaling; TB-500 modulates the actin cytoskeleton and inflammatory signaling. The combined profile is broader than either alone.

BPC-157 — Angiogenesis

Upregulates VEGFR2 expression, promoting formation of new capillaries in damaged tissues and improving local blood supply.

BPC-157 — NO Pathway

Modulates the nitric-oxide system to support endothelial function and protect against ulceration in research models.

TB-500 — Actin Mobilization

Sequesters G-actin monomers, regulating cytoskeleton turnover and enabling rapid cell migration to sites of damage.

TB-500 — Inflammation

Modulates inflammatory signaling and supports differentiation of progenitor cells into reparative phenotypes.

Research Effects on the Body

Endpoints reported across regenerative-research literature.

Tendon and ligament repair: accelerated healing in animal models of tendinopathy and partial tear.
Muscle recovery: faster restoration of contractile function following research-induced injury.
Gastrointestinal protection: BPC-157 reduces lesions in gastric and intestinal injury models.
Vascular regrowth: documented angiogenic response in ischemic and wound models.
Connective-tissue support: improved fibroblast activity and collagen organization.
Inflammation modulation: reduced pro-inflammatory signaling at injury sites.

Reconstitution — Dilution Math

The 20 mg blend (10 mg BPC-157 + 10 mg TB-500) is reconstituted with bacteriostatic water. Each volume below splits proportionally between the two peptides. Units refer to insulin syringe (1 mL = 100 IU).

Bac Water	Total Concentration	Per peptide	500 mcg blend	1 mg blend
1 mL	20 mg/mL	10 mg/mL each	0.025 mL · 2.5 IU	0.05 mL · 5 IU
2 mL	10 mg/mL	5 mg/mL each	0.05 mL · 5 IU	0.10 mL · 10 IU
4 mL	5 mg/mL	2.5 mg/mL each	0.10 mL · 10 IU	0.20 mL · 20 IU

Standardized 20 mg working reference: a 1 mL reconstitution gives the 20 mg/mL baseline used across the Peptisynlab catalog (here split as 10 mg BPC-157 + 10 mg TB-500 per mL).

Dosing Reference (Research Context)

Dose ranges from regenerative-peptide research literature, listed for laboratory reference only.

Phase	Reported Range	Typical Frequency	Vial Duration (20 mg)
Maintenance	250 – 500 mcg blend	Once daily	40 – 80 days
Active repair	500 mcg – 1 mg blend	1–2× daily	10 – 40 days
Loading phase	1 – 2.5 mg blend	Twice weekly	4 – 10 weeks

Half-Life, Onset and Duration

BPC-157: short plasma half-life (~4 hours) but research literature describes a tissue effect that significantly outlasts circulating levels.

TB-500: moderate half-life of several hours; protocols typically space larger doses 2–3 days apart.

Onset: early effects observable within days in tissue-repair models.

Duration of effect: reparative outcomes accumulate over multi-week research courses.

Storage & Stability

Lyophilized vial: store at −20 °C for long-term stability. Refrigeration (2–8 °C) acceptable for short-term storage.
Reconstituted solution: store at 2–8 °C; use within 21 – 28 days.
Light: protect from direct light.
Handling: swirl gently to dissolve; do not shake aggressively.

Important Considerations

Research Use Only. The information presented is for in-vitro and laboratory-research contexts. This blend is not a finished pharmaceutical product, is not intended for diagnosis, treatment or prevention of disease, and is not for human or veterinary use.